ClinicalTrials.gg
CompletedNCT00937027Updated Sep 20, 2019

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

A Phase 1 interventional study of Aminopterin in Psoriasis, sponsored by Syntrix Biosystems, Inc.. Completed at 1 site in United States. Open to participants aged 21 Years to 59 Years. Per ClinicalTrials.gov, last updated 2019-09-20.

Sponsored by Syntrix Biosystems, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
21 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 766 studies in Psoriasis with a site in United States — 57 open to participants now, 88 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
535th of 675
22 · median 77
Started
2009
with 29 others
Phase 1
86 of 766
6 open now
Registered
141st of 766
by date

Among the 766 studies in Psoriasis with a site in United States, this one is the 535th largest by enrollment of the 675 interventional ones that give a count, is one of 30 that started in 2009, is one of 86 in phase 1, and was the 141st registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

57 of the 766 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 21 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 766 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and pharmacokinetic properties (the absorption, distribution and excretion) of two preparations of aminopterin (0.25 mg tablets and 1.0 mg tablets) following oral administration by subjects with moderate to severe psoriasis.

03

Conditions studied

  • Psoriasis

Keywords

  • Antifolate
  • Psoriasis
  • Antiinflammatory drug
  • Autoimmune disease
  • Treatment
04

Who can participate

Ages eligible
21 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Give written by signing an IRB-approved Informed Consent.
  • Be under treatment for at least moderate to severe psoriasis (diagnosis confirmed by a dermatologist) with MTX (10-20 mg per week) for a minimum of 3 months. Moderate to severe psoriasis is defined here as plaque-type psoriasis affecting a body surface area > 10%.
  • Be 21 years of age or older, but not 60 years of age or older.
  • If participant is female of child bearing potential, then subject must indicate that she is not pregnant.
  • Must be fully informed of the potential for AMT to adversely affect a fetus, and must agree to use highly effective method of beginning at the time of consent, during the study, and for 3 months after leaving the study.
  • Women of may enter the study only after a confirmed menstrual period, and must have a negative urine pregnancy test at the time of screening and within 24 hours of each study drug dose.
  • Have adequate hematologic function as evidenced by the following :results obtained from a blood sample drawn within 2 days of day 0:

    • WBC > 4,500/ mm3
    • Count > 150,000/mm3
    • > 12.0 gm/dL
  • Have adequate liver function as evidenced by the following results obtained from a blood sample drawn within 2 days of day 0:

    • (SGOT) ≤ 40 IU/L
    • ALT (SGPT) ≤ 40 IU/L
    • Alkaline Phosphatase ≤ 120 IU/L
    • Total ≤ 1.2 mg/dL
  • Have adequate renal function as evidenced by the following result obtained from a blood sample drawn within 2 days of day 0:

    • estimated by formula:
    • > 90 ml/min (male)
    • > 90 ml/min (female)
  • Have no detectable urine glucose, urine ketones, or urine protein from a sample obtained within 2 days of day 0.
  • Weight of 35 to 90 kg.

Exclusion criteria

Exclusion Criteria:

  • A known history of hepatitis, liver fibrosis or cirrhosis (grades IIIA, IIIB or IV), diabetes (type I or II), infection, tuberculosis, interstitial lung disease, or an abnormal screening chest x-ray that is consistent with interstitial lung disease.
  • Known peptic ulcer, ulcerative colitis or Crohn's disease.
  • (BMI) \<19.0 or > 35.0 (see appendix C).
  • Within 2 weeks prior to randomization use of any of the following medications that may result in drug/drug interactions with aminopterin: methotrexate, trimethoprim with or without sulfamethoxazole; sulfonamides; sulfonylureas; pyrimethamine; triamethamine; dipyridamole; colchicine; probenecid; aminoglycosides; theophylline; phenytoin; and folinic acid (i.e., leucovorin) unless prescribed by the investigator to treat study drug related toxicity.
  • Within 2 weeks prior to randomization use of salicylates, non-steroidal anti-inflammatory (NSAID) drugs, including Over-The-Counter nonprescription use of aspirin, ibuprofen or naproxen.
  • Use of medications that may be negatively influenced by regular folic acid supplementation such as the anti-epileptics phenobarbital, diphenylhydantoin, and primidone.
  • Use of any medication within 30 days prior to admission to the study.
  • Inability to abstain from alcohol during the study.
  • A history of substance abuse, drug addiction or alcoholism.
  • Unwillingness to use an adequate form of during the study and for 3 months after the study.
  • A female who is pregnant, intends to become pregnant during the study (or within 6 months after study completion), or nursing.
  • Concurrent participation in another clinical trial involving experimental treatment.
  • Current and uncontrolled infection, cardiovascular, pulmonary, hepatic or GI conditions that will interfere with the conduct of the trial or pose an additional morbid risk.
  • Any renal conditions that will interfere with the conduct of the trial or pose an additional morbid risk.
  • Any concurrent disease or condition that in the opinion of the investigator impairs the subject's ability to complete the trial. Psychological, familial, sociological, geographical or medical conditions which, in the Investigator's opinion, could compromise compliance with the objectives and procedures of this protocol or obscure interpretation of the trial's data.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Active comparator
    Aminopterin one 1.0 mg tablet

    Drug: Aminopterin

  • Active comparator
    Aminopterin 1 four 0.25 mg tablets

    Drug: Aminopterin

Interventions

  • oral tablets, 1.0 mg dose, once weekly, two weeks

06

What researchers measure

Primary outcomes

  1. Aminopterin area under the curve

    Time frame: 0.0, 0.5, 1.0, 1.5, 2.0, 3.0, 5.0, 7.0, 10.0 and 12.0 hours

  2. Adverse events

    Time frame: 14 days

Secondary outcomes

  1. Aminopterin concentration maximum, time to maximal aminopterin concentration, aminopterin volume of distribution and aminopterin half-life.

    Time frame: 0.0, 0.5, 1.0, 1.5, 2.0, 3.0, 5.0, 7.0, 10.0 and 12.0 hours

07

Study locations

1 site
  • Baylor Research Institute
    Dallas, Texas 75246, United States
08

References and documents

Publications

  • Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangjee A, Morgan JR, Maeda DY, Schuler AD, Kahn SJ, Zebala JA. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther. 2012 Sep;342(3):696-708. doi: 10.1124/jpet.112.195479. Epub 2012 May 31. PubMed 22653877 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2009
First posted
Jul 10, 2009
Start
Jun 2009
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Last update
Sep 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00937027
Lead sponsor
Syntrix Biosystems, Inc.
Responsible party
Sponsor
First posted
Jul 10, 2009
Start date
Jun 2009
Primary completion
Apr 2010
Completion
Apr 2010
Last update
Sep 20, 2019

Study contacts

Alan Menter, M.D.
principal investigator · Baylor Research Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminopterin

Start the discussion